Dendritic cells as therapeutic vaccines against cancer.
Mouse studies have shown that the immune system can reject tumours, and the identification of tumour antigens that can be recognized by human T cells has facilitated the development of immunotherapy protocols. Vaccines against cancer aim to induce tumour-specific effector T cells that can reduce the tumour mass, as well as tumour-specific memory T cells that can control tumour relapse. Owing to their capacity to regulate T-cell immunity, dendritic cells are increasingly used as adjuvants for vaccination, and the immunogenicity of antigens delivered by dendritic cells has now been shown in patients with cancer. A better understanding of how dendritic cells regulate immune responses will allow us to better exploit these cells to induce effective antitumour immunity.
Banchereau
Jacques
J
Baylor Institute for Immunology Research, 3434 Live Oak, Dallas, Texas 75204, USA. jacquesb@baylorhealth.edu
Palucka
A Karolina
AK
D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D019496:Cancer Vaccines